S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20

Merck & Co., Inc. Stock Forecast, Price & News

$79.16
-3.12 (-3.79%)
(As of 11/26/2021 04:00 PM ET)
Add
Compare
Today's Range
$77.11
$79.93
50-Day Range
$71.93
$90.54
52-Week Range
$70.89
$91.40
Volume
18.02 million shs
Average Volume
12.44 million shs
Market Capitalization
$199.95 billion
P/E Ratio
27.97
Dividend Yield
3.16%
Beta
0.46
30 days | 90 days | 365 days | Advanced Chart
Receive MRK News and Ratings via Email

Sign-up to receive the latest news and ratings for Merck & Co., Inc. and its competitors with MarketBeat's FREE daily newsletter.


Merck & Co., Inc. logo

About Merck & Co., Inc.

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Headlines

Johnson & Johnson to split into 2 companies
November 12, 2021 |  marketbeat.com
3 COVID Stock Plays That Are Here to Stay (MRK)
November 5, 2021 |  marketbeat.com
Merck Slumps on Covid Pill’s Lower Efficacy, FDA Scrutiny
November 26, 2021 |  finance.yahoo.com
Merck & Co., Inc. (NYSE:MRK) PT Raised to $95.00 at Truist
November 24, 2021 |  americanbankingnews.com
Why You Can't Afford Not to Buy Merck's Stock
November 23, 2021 |  msn.com
Merck Completes Acquisition of Acceleron Pharma Inc.
November 22, 2021 |  finance.yahoo.com
Is Merck Stock a Buy?
November 20, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
CUSIP
58933Y10
Employees
74,000
Year Founded
1891

Sales & Book Value

Annual Sales
$47.99 billion
Cash Flow
$7.11 per share
Book Value
$14.20 per share

Profitability

Net Income
$7.07 billion
Pretax Margin
20.25%

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares
2,525,944,000
Free Float
2,517,861,000
Market Cap
$199.95 billion
Optionable
Optionable

Company Calendar

Ex-Dividend
9/14/2021
Dividend Payable
10/07/2021
Last Earnings
10/27/2021
Today
11/27/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
2/03/2022

Social Links


MarketRank

Overall MarketRank

3.12 out of 5 stars

Medical Sector

14th out of 1,391 stocks

Pharmaceutical Preparations Industry

2nd out of 669 stocks

Analyst Opinion: 3.4Community Rank: 4.5Dividend Strength: 3.3Insider Behavior: 2.5Valuation: 1.9 5 -4 -3 -2 -1 -












Merck & Co., Inc. (NYSE:MRK) Frequently Asked Questions

Is Merck & Co., Inc. a buy right now?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merck & Co., Inc. in the last twelve months. There are currently 3 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Merck & Co., Inc. stock.
View analyst ratings for Merck & Co., Inc.
or view top-rated stocks.

How has Merck & Co., Inc.'s stock price been impacted by Coronavirus?

Merck & Co., Inc.'s stock was trading at $79.25 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, MRK stock has decreased by 0.1% and is now trading at $79.16.
View which stocks have been most impacted by COVID-19
.

When is Merck & Co., Inc.'s next earnings date?

Merck & Co., Inc. is scheduled to release its next quarterly earnings announcement on Thursday, February 3rd 2022.
View our earnings forecast for Merck & Co., Inc.
.

How were Merck & Co., Inc.'s earnings last quarter?

Merck & Co., Inc. (NYSE:MRK) announced its quarterly earnings results on Wednesday, October, 27th. The company reported $1.75 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $1.55 by $0.20. The firm had revenue of $13.15 billion for the quarter, compared to the consensus estimate of $12.32 billion. Merck & Co., Inc. had a trailing twelve-month return on equity of 48.21% and a net margin of 14.64%. The business's quarterly revenue was up 4.8% on a year-over-year basis. During the same period in the previous year, the business earned $1.74 EPS.
View Merck & Co., Inc.'s earnings history
.

How often does Merck & Co., Inc. pay dividends? What is the dividend yield for Merck & Co., Inc.?

Merck & Co., Inc. announced a quarterly dividend on Tuesday, July 27th. Investors of record on Wednesday, September 15th will be paid a dividend of $0.65 per share on Thursday, October 7th. This represents a $2.60 annualized dividend and a yield of 3.28%. The ex-dividend date of this dividend is Tuesday, September 14th.
View Merck & Co., Inc.'s dividend history
.

Is Merck & Co., Inc. a good dividend stock?

Merck & Co., Inc. pays an annual dividend of $2.60 per share and currently has a dividend yield of 3.16%. Merck & Co., Inc. has been increasing its dividend for 10 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio of Merck & Co., Inc. is 91.87%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, Merck & Co., Inc. will have a dividend payout ratio of 39.16% next year. This indicates that Merck & Co., Inc. will be able to sustain or increase its dividend.
View Merck & Co., Inc.'s dividend history.

What guidance has Merck & Co., Inc. issued on next quarter's earnings?

Merck & Co., Inc. updated its FY 2021 earnings guidance on Thursday, November, 4th. The company provided EPS guidance of $5.650-$5.700 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $5.770. The company issued revenue guidance of $47.40 billion-$47.90 billion, compared to the consensus revenue estimate of $48.16 billion.

What price target have analysts set for MRK?

11 brokers have issued 12 month price targets for Merck & Co., Inc.'s stock. Their forecasts range from $90.00 to $110.00. On average, they anticipate Merck & Co., Inc.'s share price to reach $97.10 in the next twelve months. This suggests a possible upside of 22.7% from the stock's current price.
View analysts' price targets for Merck & Co., Inc.
or view top-rated stocks among Wall Street analysts.

Who are Merck & Co., Inc.'s key executives?

Merck & Co., Inc.'s management team includes the following people:
  • Robert M. Davis, President, Chief Executive Officer & Director
  • Caroline A. Litchfield, Chief Financial Officer & Executive Vice President
  • Sandy Tremps, Vice President-R&D IT CIO
  • Dave Williams, Chief Information & Digital Officer
  • Franklin K. Clyburn, Executive VP & President-Human Health

What is Kenneth C. Frazier's approval rating as Merck & Co., Inc.'s CEO?

1,343 employees have rated Merck & Co., Inc. CEO Kenneth C. Frazier on Glassdoor.com. Kenneth C. Frazier has an approval rating of 94% among Merck & Co., Inc.'s employees. This puts Kenneth C. Frazier in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Merck & Co., Inc. own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Merck & Co., Inc. investors own include Pfizer (PFE), Johnson & Johnson (JNJ), AT&T (T), Intel (INTC), Cisco Systems (CSCO), Walt Disney (DIS), Verizon Communications (VZ), JPMorgan Chase & Co. (JPM), AbbVie (ABBV) and Home Depot (HD).

What is Merck & Co., Inc.'s stock symbol?

Merck & Co., Inc. trades on the New York Stock Exchange (NYSE) under the ticker symbol "MRK."

Who are Merck & Co., Inc.'s major shareholders?

Merck & Co., Inc.'s stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.42%), Wellington Management Group LLP (1.96%), Geode Capital Management LLC (1.69%), Franklin Resources Inc. (1.55%), Bank of New York Mellon Corp (1.16%) and Morgan Stanley (1.03%). Company insiders that own Merck & Co., Inc. stock include Caroline Litchfield, Frank Clyburn, Julie L Gerberding, Kenneth C Frazier, Richard R Deluca, Rita A Karachun, Robert M Davis, Sanat Chattopadhyay and Wendell P Weeks.
View institutional ownership trends for Merck & Co., Inc.
.

Which institutional investors are selling Merck & Co., Inc. stock?

MRK stock was sold by a variety of institutional investors in the last quarter, including American International Group Inc., AMF Pensionsforsakring AB, Geode Capital Management LLC, Prospera Financial Services Inc, KBC Group NV, Man Group plc, Hsbc Holdings PLC, and Schroder Investment Management Group. Company insiders that have sold Merck & Co., Inc. company stock in the last year include Caroline Litchfield, Frank Clyburn, Kenneth C Frazier, Richard R Deluca, Rita A Karachun, and Sanat Chattopadhyay.
View insider buying and selling activity for Merck & Co., Inc.
or view top insider-selling stocks.

Which institutional investors are buying Merck & Co., Inc. stock?

MRK stock was purchased by a variety of institutional investors in the last quarter, including Nordea Investment Management AB, Invesco Ltd., Capital World Investors, Marathon Asset Mgmt Ltd, Credit Suisse AG, California Public Employees Retirement System, Bank of Nova Scotia, and Arrowstreet Capital Limited Partnership.
View insider buying and selling activity for Merck & Co., Inc.
or or view top insider-buying stocks.

How do I buy shares of Merck & Co., Inc.?

Shares of MRK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Merck & Co., Inc.'s stock price today?

One share of MRK stock can currently be purchased for approximately $79.16.

How much money does Merck & Co., Inc. make?

Merck & Co., Inc. has a market capitalization of $199.95 billion and generates $47.99 billion in revenue each year. The company earns $7.07 billion in net income (profit) each year or $2.83 on an earnings per share basis.

How many employees does Merck & Co., Inc. have?

Merck & Co., Inc. employs 74,000 workers across the globe.

When was Merck & Co., Inc. founded?

Merck & Co., Inc. was founded in 1891.

What is Merck & Co., Inc.'s official website?

The official website for Merck & Co., Inc. is www.merck.com.

Where are Merck & Co., Inc.'s headquarters?

Merck & Co., Inc. is headquartered at 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033.

How can I contact Merck & Co., Inc.?

Merck & Co., Inc.'s mailing address is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. The company can be reached via phone at (908) 740-4000, via email at [email protected], or via fax at 908-735-1253.


This page was last updated on 11/27/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.